Close Menu

Invitae

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.

The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.

Missed a Few

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

The company accessioned approximately 78,000 samples in Q3 2018, up 95 percent from the year-ago quarter when it accessioned 40,000 samples..

Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost.

The company plans to use the technology, originally developed by Good Start Genetics, to offer sample preparation solutions and data analysis for NGS.

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.

Based on the strength of its quarterly financial performance, Invitae said it is now expecting annual revenues of between $135 million and $140 million for 2018.

Pages

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.